公开(公告)号：US20230181634A1

公开(公告)日：2023-06-15

申请号：US16617487

申请日：2018-05-31

Applicant: Pfizer Inc.

Inventor： Barbra Johnson SASU ,  Danielle Elizabeth DETTLING ,  Cesar Adolfo SOMMER ,  Yik Andy YEUNG ,  Moustafa Marc HAMZE

IPC: A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C07K14/705 ,  C07K14/715 ,  A61K39/395 ,  A61K45/06 ,  A61P35/02

CPC classification number: A61K35/17 ,  C07K14/7051 ,  C07K16/2863 ,  C07K14/70517 ,  C07K14/7151 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/02 ,  C07K2317/622 ,  A61K38/00

Abstract: Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).